Compound Monograph
Hirsutine
Hirsutine is a corynanthe-type indole alkaloid of Uncaria (mainly the Chinese gou teng, U. rhynchophylla; also cat's claw and gambir). Its best-characterized action is cardiovascular — a calcium-channel-blocking vasorelaxant with antiarrhythmic properties in isolated tissue — with a notable secondary antiviral signal (anti-influenza A and anti-dengue in vitro). It is chemically distinct from Uncaria's oxindole alkaloids and, despite a shared scaffold with kratom's mitragynine, has no opioid activity. All evidence is preclinical.
Sources · 3
Where Does It Come From?
Hirsutine is a naturally occurring indole alkaloid (corynanthe-type), found in Cat's Claw, Uncaria rhynchophylla and Uncaria gambir. It is well tolerated orally (low toxicity).
Concentration
Content by Source
Concentrations not reported. No percent-dry-weight or mg/g figures have been published for this compound in its source plants.
Hirsutine at a Glance
Hirsutine is a corynanthe-type indole alkaloid of Uncaria — mainly the Chinese gou teng, and also present in cat’s claw and gambir.
Its best-characterised action is cardiovascular: a calcium-channel-blocking vasorelaxant effect that provides a coherent pharmacological basis for gou teng’s traditional use in hypertension and “liver-yang rising” patterns.
Its research is preclinical.
What It's Used For
Hirsutine is a corynanthe-type indole alkaloid of Uncaria — mainly the Chinese U. rhynchophylla (gou teng), also present in cat’s claw and gambir. Class discipline matters: it is chemically and pharmacologically distinct from the oxindole alkaloids of Amazonian cat’s claw (its co-alkaloid mitraphylline, plus rhynchophylline and pteropodine); and although hirsutine and kratom’s mitragynine share a Rubiaceae corynanthe-indole scaffold, hirsutine has no reported opioid activity — kratom pharmacology must not be read onto it. Its best-characterized action is cardiovascular (a calcium-channel-blocking vasorelaxant), with a notable secondary antiviral signal; all evidence is preclinical.
Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No human isolate data, so scores stay low by design.
Hirsutine’s classic and best-characterized signal. In isolated rat aorta it produces dose-dependent, endothelium-independent relaxation of noradrenaline- and high-K⁺-induced contraction, acting mainly as a voltage-dependent Ca²⁺-channel blocker and also reducing intracellular Ca²⁺-store release 2,
Gap: all in-vitro/animal (rat isolated tissue), with no human isolate blood-pressure or arrhythmia trial and modest (µM-range) potency 2,
The genuine hook beyond cardiovascular. Against dengue virus, hirsutine inhibits a late step of the lifecycle (assembly/budding/release, not replication) across serotypes at low-µM EC50 5Reference 5Hirsutine, an indole alkaloid of Uncaria rhynchophylla, inhibits a late step in the dengue-virus lifecycleView study →; against influenza A (H3N2) it was reported more potent than ribavirin, a finding echoed in the total-synthesis literature that titles it “the active anti-influenza A virus indole alkaloid” 6Reference 6Highly efficient enantioselective total synthesis of the active anti-influenza-A-virus indole alkaloid hirsutineView study →.
Gap: in-vitro/cell-culture only, with the influenza figure a secondary/older report and no in-vivo antiviral or human data 5,
Hirsutine was identified as an anti-metastatic phytochemical targeting NF-κB (p65) and suppressing MMP-2/MMP-9 in a murine breast-cancer model 7Reference 7Identification of hirsutine as an anti-metastatic phytochemical by targeting NF-κB activationView study →, induces mitochondrial-permeability-transition-dependent apoptosis via ROCK1/PTEN/PI3K/GSK3β in lung cancer cells 8Reference 8Hirsutine induces mPTP-dependent apoptosis through the ROCK1/PTEN/PI3K/GSK3β pathway in human lung cancer cellsView study →, and is antiproliferative in Jurkat leukemia cells 9Reference 9Inhibitory effect and mechanism of hirsutine on the proliferation of T-cell leukaemia Jurkat clone E6-1 cellsView study →.
Gap: cell-line and single-mouse-model level, with no isolate clinical oncology data — do not imply clinical use 7,
Hirsutine crosses the blood-brain barrier (low but measurable brain levels in mice) 11Reference 11AnimalTissue distribution of hirsutine and hirsuteine in mice by UHPLC-MSView study →, giving biological plausibility.
Gap: essentially no direct hirsutine neuroprotection dataset — the well-documented Uncaria neuroprotection belongs to the sibling alkaloids rhynchophylline/isorhynchophylline, so this is speculative for hirsutine 11Reference 11AnimalTissue distribution of hirsutine and hirsuteine in mice by UHPLC-MSView study →.
Mechanisms
| Target / pathway | Effect | Relevant to |
|---|---|---|
| Voltage-dependent Ca²⁺ channel (vascular smooth muscle) | blocked → endothelium-independent vasorelaxation | antihypertensive / vasodilatory |
| Intracellular Ca²⁺ stores | reduced release → lower cytosolic Ca²⁺ | vasorelaxation; possible antiviral link |
| Cardiac action potential (SA node/atrium/ventricle) | negative chronotropy, prolonged APD | antiarrhythmic |
| DENV late lifecycle (assembly/budding/release) | inhibited without blocking replication | anti-dengue |
| Influenza A (H3N2) replication | inhibited (mechanism unresolved) | anti-influenza |
| NF-κB (p65) → MMP-2/MMP-9; ROCK1/PTEN/PI3K/GSK3β → mPTP | suppressed; pro-apoptotic | anticancer (preclinical) |
Pharmacokinetics
Hirsutine’s pharmacokinetics are characterized only in rodents. In rats it undergoes extensive phase-I metabolism (oxidation/demethylation) to multiple metabolites 10Reference 10AnimalMetabolites of hirsuteine and hirsutine, the major indole alkaloids of Uncaria rhynchophylla, in ratsView study →; in mice (10 mg/kg IP), tissue distribution is highest in liver and kidney, with low but clearly present brain levels indicating BBB penetration 11Reference 11AnimalTissue distribution of hirsutine and hirsuteine in mice by UHPLC-MSView study →. A Uncaria-alkaloid review notes generally modest oral bioavailability typical of the class with hepatic/renal handling 12Reference 12Properties, pharmacology and pharmacokinetics of active indole and oxindole alkaloids in Uncaria hookView study →, and there is no validated human pharmacokinetics.
Clinical trials
There are no human trials of isolated hirsutine; all cardiovascular, antiviral and anticancer data are in-vitro or animal, and human Uncaria data pertain to whole extracts, not this molecule.
| Completed | Planned | Terminated | Preclinical |
|---|---|---|---|
| —(none, isolate) | — | — | Modest(cardiovascular + antiviral) |
Last checked: July 2026.
Toxicity & Safety
No documented harm has been reported, but hirsutine is genuinely cardioactive — a calcium-channel blocker that slows the heart and prolongs cardiac action-potential duration — so the plausible risks come from its pharmacology rather than from any toxicity signal.
- Not mitragynine. Despite the shared corynanthe-indole scaffold, hirsutine has no reported opioid activity, and kratom’s dependence profile does not apply.
- Cardioactive at pharmacological exposures. Plausible hypotension, bradycardia and conduction effects follow directly from its calcium-channel blockade.
- Avoid in pregnancy and lactation. No reproductive data.
- Additive with cardiovascular drugs. Calcium-channel blockers, antihypertensives and antiarrhythmics.
- No dedicated toxicology. No LD50 for the isolate was located; cytotoxicity thresholds in the research sit in the low-µM range.
Full Safety & Interactions Detail
Hirsutine has a low verdict on the available preclinical data — no dedicated toxicology or LD50 for the isolate was located, and cytotoxicity thresholds in the antiviral/anticancer work sit in the low-µM range. The honest qualifier is pharmacology, not documented harm: hirsutine is genuinely cardioactive — a Ca²⁺-channel blocker that is negatively chronotropic and prolongs cardiac action-potential duration 2,
Dosage
There is no established human dose for isolated hirsutine, and it is not a standalone supplement. Evidence exists only as in-vitro concentrations (low-µM vasorelaxation; dengue EC50 ~1.9 µM) and animal doses (e.g. mouse 10 mg/kg IP for pharmacokinetics) — none of which is an oral human recommendation.
References
- Endo K, et al. (1983). Hypotensive principles of Uncaria hooks. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/6657789/
- Yano S, Horiuchi H, Horie S, et al. (1991). Ca²⁺-channel-blocking effects of hirsutine, an indole alkaloid from the Uncaria genus, in the isolated rat aorta. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/1798789/
- Horie S, Yano S, Aimi N, et al. (1992). Effects of hirsutine, an antihypertensive indole alkaloid from Uncaria rhynchophylla, on intracellular calcium in rat thoracic aorta. Life Sciences. https://pubmed.ncbi.nlm.nih.gov/1311793/
- Masumiya H, Saitoh T, Tanaka Y, et al. (1999). Effects of hirsutine and dihydrocorynantheine on the action potentials of sino-atrial node, atrium and ventricle. Life Sciences. https://pubmed.ncbi.nlm.nih.gov/10597888/
- Hishiki T, et al. (2017). Hirsutine, an indole alkaloid of Uncaria rhynchophylla, inhibits a late step in the dengue-virus lifecycle. Frontiers in Microbiology. https://pubmed.ncbi.nlm.nih.gov/28912773/
- Tietze LF, Zhou Y (1999). Highly efficient enantioselective total synthesis of the active anti-influenza-A-virus indole alkaloid hirsutine. Angewandte Chemie International Edition. https://pubmed.ncbi.nlm.nih.gov/34182696/
- Lou C, Takahashi K, Irimura T, et al. (2014). Identification of hirsutine as an anti-metastatic phytochemical by targeting NF-κB activation. International Journal of Oncology. https://pubmed.ncbi.nlm.nih.gov/25175557/
- Zhang R, Li G, Zhang Q, et al. (2018). Hirsutine induces mPTP-dependent apoptosis through the ROCK1/PTEN/PI3K/GSK3β pathway in human lung cancer cells. Cell Death & Disease. https://pubmed.ncbi.nlm.nih.gov/29789524/
- Meng J, Su R, Wang L, et al. (2021). Inhibitory effect and mechanism of hirsutine on the proliferation of T-cell leukaemia Jurkat clone E6-1 cells. PeerJ. https://pubmed.ncbi.nlm.nih.gov/33604171/
- Nakazawa T, Banba K, Hata K, et al. (2006). Metabolites of hirsuteine and hirsutine, the major indole alkaloids of Uncaria rhynchophylla, in rats. Biological & Pharmaceutical Bulletin. https://pubmed.ncbi.nlm.nih.gov/16880624/
- Zhou Q, Ma J, Chen L (2020). Tissue distribution of hirsutine and hirsuteine in mice by UHPLC-MS. Journal of Analytical Methods in Chemistry. https://pubmed.ncbi.nlm.nih.gov/32399311/
- Kushida H, Matsumoto T, Ikarashi Y (2021). Properties, pharmacology and pharmacokinetics of active indole and oxindole alkaloids in Uncaria hook. Frontiers in Pharmacology. https://pubmed.ncbi.nlm.nih.gov/34335255/
